

**NOTE: INFORMATION EMBARGOED UNTIL OCTOBER 29th 2019, 6:00 p.m.
Eastern US time (11 p.m. in Paris)**

Paris, 29 October 2019

Press information

Pediatric Cancers: Why Some Forms of Leukemia Only Affect Children

Acute myeloid leukemia (AML) mainly affects children, with the prognosis often being poor despite several decades of research into more effective treatments. A new study led by Thomas Mercher (Inserm U1170/Gustave Roussy/Université Paris-Sud-Paris Saclay), and performed in collaboration with Jürg Schwaller (UKBB, Department of Biomedicine, Universität Basel) explains why some forms of leukemia develop in very young children. The study – published in *Cancer Discovery*, a journal of the American Association for Cancer Research – has also revealed potential new therapeutic targets.

Each year, 2,500 pediatric cancers are diagnosed in France, with one third of cases concerning leukemia – commonly known as blood cancer. Over recent decades, research into pediatric cancer has intensified and treatments have improved, but the prognosis remains particularly unfavorable for these young patients.

Acute myeloid leukemia (AML) accounts for 15% of cases of leukemia diagnosed in children and adolescents. Overall survival at 5 years is around 60%, with relapse being the most common cause of mortality.

Abnormal protein fusion

There are several subtypes of AML. One of the most aggressive, which is linked to treatment resistance and a particularly unfavorable prognosis, is acute megakaryoblastic leukemia (AML-M7). In their new study published in *Cancer Discovery*, the team focused their efforts specifically on this type of acute myeloid leukemia. Their work is co-financed by the National League Against Cancer.

Through the [CONNECT-AML collaborative network¹](#), the scientists obtained samples from young patients with AML-M7. In 2012, their analysis of these samples had already revealed AML-M7 to frequently present genetic alterations that lead to the expression of an abnormal protein resulting from the fusion of the two proteins normally independent in the cell. At that time, although this fusion – known as ETO2-GLIS2 –

¹ French network of various teams of researchers, clinical pathologists and pediatric hematologists

had been identified in 30% of AML-M7 cases, the researchers could not explain its mechanism of action.

They also wanted to understand why AML-M7 is diagnosed in children who are on average a lot younger (under 2 years of age) than those diagnosed with the other pediatric AML subtypes (on average towards the age of 6).

"One of the objectives of our new study was to look at the mechanism of action of the ETO2-GLIS2 fusion, and to better elucidate its consequences. We wanted to answer two major questions, with the first being why this disease is specific to children – since the fusion is not found in adults, and then what the potential therapeutic avenues could be", explains Thomas Mercher.

This involved the researchers analyzing the characteristics of human leukemia cells and developing a mouse model to study the consequences of the ETO2-GLIS2 fusion.

Towards new therapeutic avenues

In this model, the researchers showed that this fusion is sufficient in order to rapidly induce aggressive leukemia, if it is activated in fetal hematopoietic cells. However, there is little to link its activation in adult cells with the development of leukemia. Moreover, blocking the ETO2-GLIS2 fusion in the *in vivo* model brings tumor proliferation to a halt, with the abnormal blood cells once again able to differentiate into normal blood cells.

These findings suggest that some forms of leukemia develop specifically in children because the properties of the fetal cells differ from those of adult cells.

Findings which also make it possible to propose new target mechanisms in fetal cells and pediatric leukemia in order to improve treatments for these patients. *"We now want to understand exactly how this fusion works. Targeting it in order to directly inhibit it with molecules that could be used in patients is not something we are able to do at present, so instead we will identify and try to target the surrounding proteins that are important for it to function",* concludes Thomas Mercher.

Sources

Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia

Cécile K. Lopez^{1,2,3,4}, Esteve Noguera^{1,2,4}, Vaia Stavropoulou⁵, Elie Robert^{1,2,4}, Zakia Aid^{1,2,4}, Paola Ballerini⁶, Chrystèle Bilhou-Nabera⁷, Hélène Lapillonne⁷, Fabien Boudia^{1,2,4,9}, Cécile Thirant^{1,2,4}, Alexandre Fagnan^{1,2,4,9}, Marie-Laure Arcangeli¹⁰, Sarah J. Kinston¹¹, M'Boyba Diop², Bastien Job², Yann Lecluse², Erika Brunet¹², Loélia Babin¹², Jean-Luc Villeval^{1,2}, Eric Delabesse¹³, Antoine H.F.M. Peters¹⁴, William Vainchenker^{1,2}, Muriel Gaudry^{1,2}, Riccardo Masetti¹⁵, Franco Locatelli¹⁶, Sébastien Malinge^{1,2,3,4}, Claus Nerlov¹⁷, Nathalie Droin¹, Camille Lobry¹, Isabelle Godin^{1,2}, Olivier A. Bernard^{1,2,3,4}, Berthold Göttgens¹¹, Arnaud Petit⁶, Françoise Pflumio¹⁰, Juerg Schwaller^{5,*}, Thomas Mercher^{1,2,4,9,*}

- 1 INSERM U1170, Gustave Roussy, 94800 Villejuif, France
- 2 Gustave Roussy, 94800 Villejuif, France
- 3 Université Paris-Saclay, 94800 Villejuif, France
- 4 Equipe labellisée Ligue Nationale Contre le Cancer, 75013 Paris, France
- 5 University Children's Hospital Beider Basel (UKBB) and Department of Biomedicine, University of Basel, 4031 Basel, Switzerland
- 6 Hôpital Trousseau, AP-HP, 75012 Paris, France
- 7 Sorbonne Université, CRSA – Unité INSERM, AP-HP, Hôpital Trousseau, F-75012 Paris
- 8 Hôpital Saint Antoine, AP-HP, 75012 Paris, France
- 9 Université Paris Diderot, 75013 Paris, France
- 10 Unité Mixte de Recherche 967 Inserm-CEA/DRF/IBFJ/IRCM/LSHL- Université Paris Diderot-Université Paris-Sud, Equipe labellisée Association Recherche contre le Cancer, 92265 Fontenay-aux-Roses Cedex, France
- 11 Wellcome and MRC Cambridge Stem Cell Institute and the Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
- 12 Genome Dynamics in the Immune System Laboratory, Institut Imagine, INSERM, UMR 1163, Université Paris Descartes, Sorbonne Paris Cité, Equipe Labellisée Ligue Contre le Cancer, 75015 Paris, France
- 13 INSERM U1037, Team 16, Center of Research of Cancerology of Toulouse, Hematology laboratory, IUCT-Oncopole, France
- 14 Friedrich Miescher Institute for Biomedical Research (FMI), 4058 Basel, Switzerland; Faculty of Sciences, University of Basel, 4056 Basel, Switzerland
- 15 Department of Pediatrics, "Lalla Seràgnoli", Hematology-Oncology Unit, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 11, 40137, Bologna, Italy
- 16 Department of Pediatrics - Sapienza - University of Rome, Hematology-Oncology - IRCCS Ospedale Bambino Gesù - Rome, Italy
- 17 MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK

Link to the embargoed article

<https://cancerdiscovery.aacrjournals.org/content/early/2019/10/25/2159-8290.CD-18-1463>

Researcher contact

Thomas Mercher
Phone: +33 1 42 11 44 83
Email: thomas.mercher@inserm.fr

Juerg Schwaller
Phone: +41 61 265 3504
Email: j.schwaller@unibas.ch

Press contact

presse@inserm.fr



Access the [Inserm press room](#)

